
    
      Comparative interventional prospective phase 3, randomised, open-label, multicentric trial
      comparing the combination of radiotherapy and pembrolizumab to pembrolizumab alone as first
      line treatment of patients with newly diagnosed head and neck squamous cell carcinoma with
      synchronous metastases.
    
  